Search Bar & Filters
Found 16 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating how a new medicine called PF-08052667 works alone or combined with Bacillus Calmette Guerin BCG andor sasanlimab in adults with a type of bladder cancer that has not spread into the muscle layer but is more likely to come back or grow. This study includes people whose cancer has returned or persisted despite standard treatments like BCG, as well as those who cannot receive or do not have access to standard treatments. The study is a phase 1 trial with three parts to test different dosing and combinations of these medicines. Participants receive PF-08052667 as an intravesical infusion directly into the bladder on days 1, 8, and 15 of a 21-day cycle. In Part 2 and Part 3, PF-08052667 is combined with BCG andor sasanlimab, with sasanlimab given as a subcutaneous injection under the skin. The study has three parts Part 1 tests increasing doses of PF-08052667 alone Part 2 tests combinations of PF-08052667 with BCG andor sasanlimab and Part 3 further explores optimal doses and combinations, including participants who have never had standard treatments. Participants will continue treatment until they choose to stop, are withdrawn for reasons such as side effects, or for up to about two years. Long-term follow-up will continue after treatment ends until loss to follow-up, death, or study completion. Researchers will monitor safety, side effects, lab results, and tumor responses, including recurrence-free and event-free survival. Participation duration varies based on individual circumstances and study progress.
Actively Recruiting
Researchers are studying muscle invasive bladder cancer to see if combining pembrolizumab, a type of immunotherapy, with radiation therapy after chemotherapy can help patients avoid bladder removal surgery. This phase II trial focuses on patients who have responded well to initial chemotherapy and aims to improve three-year bladder intact event-free survival. The study also evaluates survival rates, recurrence, and treatment side effects in participants. Participants receive photon beam radiation therapy once daily from Monday to Friday for up to 20 treatments. Pembrolizumab is given intravenously on the first day of each 21-day cycle, continuing for up to 18 cycles or about 12 months if there is no disease progression or unacceptable side effects. Before treatment, participants undergo a transurethral resection of bladder tumor TURBT and provide tissue samples. Imaging scans such as CT, MRI, or PET, along with cystoscopy and collection of urine and blood samples, are performed throughout the study. During the study, participants are closely monitored with regular assessments including imaging and questionnaires about symptoms. Follow-up visits occur every 26 weeks until two years after treatment and then annually up to five years. Researchers measure outcomes like bladder intact event-free survival, local recurrence, metastasis-free survival, overall survival, and rates of salvage cystectomy. Safety and treatment-related symptoms are tracked carefully, and specimens are collected for future research.
Actively Recruiting
Researchers are comparing two treatments, rituximab and mosunetuzumab, for patients with follicular lymphoma that has a low tumor burden. This phase III trial aims to see which treatment better helps patients avoid disease progression or worsening over time. Both drugs are monoclonal antibodies targeting cancer cells, but it is unknown which one is more effective for this condition. Participants are randomly assigned to one of two groups. One group receives rituximab intravenously on day 1 of the first cycle, then rituximab with hyaluronidase subcutaneously on days 8, 15, and 22 of the first cycle and on day 1 of later cycles cycles repeat every 56 days for up to 5 cycles. The other group receives mosunetuzumab subcutaneously on days 1, 8, and 15 of the first cycle and day 1 of later cycles cycles repeat every 21 days for up to 8 cycles. During treatment, participants have CT or PETCT scans and blood samples collected. After treatment, participants are followed every 6 months for 5 years and then yearly up to 10 years. Researchers assess progression-free survival, overall survival, response rates, event-free survival, and treatment side effects. Specimens are also collected for future research. The total participation may last up to 10 years, including long-term monitoring for disease status and safety.
Actively Recruiting
Researchers are evaluating a treatment approach for patients with locally advanced cervical cancer that has spread to nearby tissues or lymph nodes. This phase III trial compares the addition of induction chemotherapy with carboplatin, paclitaxel, and pembrolizumab before the usual chemotherapy and radiation treatment combined with pembrolizumab, followed by pembrolizumab maintenance. The study aims to determine if adding induction therapy improves progression-free survival and overall survival, while assessing safety and biomarkers related to treatment response. Participants are randomly assigned to one of two groups. One group receives standard chemoradiation with cisplatin and pembrolizumab followed by pembrolizumab maintenance. The other group receives induction chemotherapy with carboplatin, paclitaxel, and pembrolizumab before starting chemoradiation and pembrolizumab maintenance. Chemoradiation includes weekly cisplatin, radiation therapy daily for 5 weeks, and brachytherapy treatments. Pembrolizumab is given intravenously at different intervals during the treatment and maintenance phases. Throughout the study, participants undergo various imaging scans such as PET, CT, chest x-ray, and MRI, along with blood sample collections to monitor their condition. Researchers evaluate outcomes including progression-free survival, overall survival, treatment side effects, treatment completion times, and biomarker levels. After completing treatments, participants are followed up every 3 months for 2 years, then every 6 months for 3 more years to monitor long-term effects and disease status.
Actively Recruiting
Researchers are evaluating the use of lanreotide before surgery compared to surgery alone to prevent pancreatic fistulas in patients with pancreatic cancer or pancreatic lesions that might become cancerous. This phase III trial aims to see if lanreotide, a drug similar to the bodys hormone somatostatin and used in certain tumors, can reduce complications like pancreatic fistulas after distal pancreatectomy surgery. Participants are randomly assigned to receive either lanreotide or a saline placebo by a quick injection under the skin within 36 hours before their planned distal pancreatectomy. Blood samples will be taken before surgery and on the first and third days after surgery, with possible collection of pancreatic fluid on these days as well. After surgery, patients will be followed up at 4, 8, and 12 months. During the study, researchers will assess the occurrence of pancreatic fistulas within 60 days after surgery, hospital stay length, and quality of life changes using specific questionnaires. They will also monitor other postoperative complications and the time to start any additional chemotherapy. Blood, pancreatic fluid, and tissue samples will be collected for future research, with all participants monitored carefully throughout the study period.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating a Master Screening and Reassessment Protocol MSRP to improve the matching of patients with myeloid cancers, such as acute myeloid leukemia AML or myelodysplastic syndrome MDS, to appropriate clinical trials or standard treatments. This study focuses on using bone marrow and blood tests to detect biomarkers that guide treatment decisions, aiming to assign participants quickly to targeted treatment studies or standard care pathways. The study also assesses the ability to organize and process data rapidly to support treatment assignments. Participants undergo bone marrow aspiration and blood collection for rapid genetic testing to identify mutations that may be targeted by specific therapies within various substudies. If no targetable mutation is found, participants may be assigned to novel combination drug studies or continue standard of care through the Tier Advancement Pathway TAP. Treatments studied include various drug regimens involving agents such as azacitidine, venetoclax, cytarabine, daunorubicin, and others, administered intravenously, subcutaneously, or orally according to specific schedules. Some participants may also receive hematopoietic stem cell transplantation with conditioning regimens. Treatment cycles vary in length and number depending on the assigned substudy. Throughout the study, participants have multiple bone marrow aspirations, biopsies, blood sample collections, and imaging tests such as echocardiography or MUGA scans for monitoring. Researchers assess timing for treatment assignment, response rates, adverse events, and overall survival among other outcomes. The study includes ongoing reassessment to allow movement to higher tier treatment options when appropriate. Participation may last for extended periods, with some regimens continuing up to two years or more, depending on response and disease progression.
Actively Recruiting
Researchers are evaluating telitacicept, a recombinant fusion protein targeting B-cell pathways, in adults with active primary Sjogrens disease. This phase 3 trial explores telitacicepts potential to reduce B-cell activity and autoimmune effects contributing to disease symptoms. The study compares telitacicept with a placebo to assess its impact on disease activity and patient well-being. Participants are randomly assigned to receive either telitacicept or placebo via subcutaneous injection. The study is double-blind, meaning neither participants nor researchers know who receives which treatment. The primary treatment period lasts 48 weeks, during which the effects on disease activity and gland function are evaluated. Throughout the study, participants undergo assessments including the EULAR Sjogrens Syndrome Disease Activity Index ESSDAI, patient and physician disease activity evaluations, fatigue assessment, and gland function tests. Safety and efficacy are monitored regularly, with the primary outcome measured at Week 48. The total study duration extends until January 2029, allowing comprehensive evaluation of telitacicepts effects.
Actively Recruiting
Researchers are evaluating radiation therapy with or without the chemotherapy drug cisplatin in patients with stage III-IVA squamous cell carcinoma of the head and neck who have had surgery to remove their tumor. This phase II trial aims to understand if adding cisplatin to radiation therapy improves disease-free survival, especially in relation to different types of p53 gene mutations, which might affect treatment outcomes. The study also looks at side effects and explores genetic changes that could influence new treatments. Participants are randomly assigned to one of two groups one group receives intensity-modulated radiation therapy IMRT alone once daily, five days a week for six weeks, while the other group receives the same radiation schedule combined with weekly intravenous cisplatin over 1 to 2 hours for six weeks. After completing treatment without disease progression or unacceptable side effects, patients enter a follow-up period lasting up to 10 years. During the study, participants undergo assessments including surgical tumor tissue analysis for p53 mutations, imaging tests to exclude distant disease, and regular health evaluations. After treatment, patients are monitored every six months for three years and then annually for seven more years to track disease recurrence or new tumors. The main outcome measured is disease-free survival, focusing on the time from randomization to recurrence, second primary tumor, or death.
Actively Recruiting
Researchers are evaluating the effects of a study medicine called PF-08634404, given alone or combined with another antibody named ipilimumab, in adults with a type of liver cancer called hepatocellular carcinoma HCC that is locally advanced or has spread to other parts of the body. This study focuses on patients whose cancer cannot be removed by surgery and who have not yet received whole-body treatment for HCC. Participants will receive PF-08634404 either as a single treatment or together with ipilimumab. Both medicines will be given through intravenous IV infusions administered directly into a vein at clinical trial sites. Participants are randomly assigned to receive either the study medicine alone or in combination with the antibody, with dose levels given sequentially. During the study, participants will be monitored for safety and response to treatment, including adverse events and tumor response using standard criteria. Researchers will assess overall response rates, progression-free survival, and other health measures over approximately 24 months. Medical staff will also track blood tests, serum drug levels, and immune responses. Treatment and follow-up visits will include clinical assessments to understand the effects and side effects of these therapies.
1-10 of 16
1